Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01885260 · ClinicalTrials.gov registry record · Phase 2
Safety, Tolerability and Efficacy of ISIS-GCGRRx in Type 2 Diabetes
A Phase 2 study, sponsored by Ionis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 77
- Enrollment target
NCT01885260: Completed Phase 2 study, sponsored by Ionis Pharmaceuticals.
NCT01885260 is a Phase 2 study that has completed, run by Ionis Pharmaceuticals. The registered enrollment target is 77 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (42% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01885260, a Phase 2 study, has completed, sponsored by Ionis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 77 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy, safety and tolerability of ISIS-GCGRRx in combination with metformin versus placebo + metformin
Primary Outcome
Change from Baseline to Week 14
Interventions
- DRUG Placebo
- DRUG ISIS-GCGRRx - Dose Level 1
- DRUG ISIS-GCGRRx - Dose Level 2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2013-07 |
| Est. Completion | 2014-11 |
| Phase | Phase 2 |
What the finished NCT01885260 record still lists
NCT01885260 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 77 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (42% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01885260 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01885260 about?
NCT01885260 is a clinical study titled "Safety, Tolerability and Efficacy of ISIS-GCGRRx in Type 2 Diabetes". The purpose of this study is to evaluate the efficacy, safety and tolerability of ISIS-GCGRRx in combination with metformin versus placebo + metformin
What is the current status of trial NCT01885260?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 77 participants. The study started on 2013-07. Estimated completion is 2014-11.
What interventions are being tested in trial NCT01885260?
The interventions under investigation include: Placebo (DRUG), ISIS-GCGRRx - Dose Level 1 (DRUG), ISIS-GCGRRx - Dose Level 2 (DRUG).
Who is sponsoring clinical trial NCT01885260?
This trial is sponsored by Ionis Pharmaceuticals, which has 76 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01885260's enrollment target sits among peer trials
77 891st of 2000 higher than 1,108 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02127398 · 77 participants · Phase 2
Stool Transplants to Treat Refractory Clostridium Difficile Colitis
- NCT04159103 · 77 participants · Phase 1
Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia
- NCT04683003 · 77 participants · Phase 3
A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura
- NCT05004116 · 77 participants · Phase 1
A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia